The Ljubimov Laboratory is part of the Regenerative Medicine Institute Eye Program directed by Alexander Ljubimov, PhD, and affiliated with the Department of Biomedical Sciences and the Department of Surgery. The program comprises three labs studying diabetic eye disease (Ljubimov), mechanisms and genetic factors of keratoconus (Yaron Rabinowitz, MD), and stem cells as therapies for retinal degenerative diseases (Shaomei Wang, MD, PhD).
We have active collaboration with the Nanomedicine Research Center at the Department of Neurosurgery. This study deals with a novel targeted nanobiopolymer, Polycefin, for the diagnosis and treatment of cancer and pathological angiogenesis. The polymer bearing various antisense oligos caninhibit growth of human brain, breast, and triple negative breast tumors in mouse models. We are designing a similar nanobiopolymer to treat choroidal neovascularization in a mouse model of wet macular degeneration. A test polymer was able to home to neovascularization sites after intravenous injection.
We have an ongoing collaboration with the RMI iPSC core, as well as with Svendsen Laboratory and Rabinowitz Laboratory. The study concerns our joint effort on developing a new source of corneal epithelial stem cells.
We collaborate with the Alzheimer's disease lab at the Department of Neurosurgery. This study concerns imaging of Alzheimer's disease through the eye using amyloid plaque-binding curcumin. A similar collaboration is ongoing with Wang Laboratory in the RMI.